BriaCell Therapeutics Corp. carries no debt; cash flow comfortably covers obligations.

BriaCell Therapeutics Corp.'s free cash flow has decreased 16.32% from $-33.59M last year to $-39.07M, signaling decreasing performance

BriaCell Therapeutics Corp.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

BriaCell Therapeutics Corp. has insufficient data to evaluate this check.

BriaCell Therapeutics Corp. has a net cash position, so leverage is healthy.

BriaCell Therapeutics Corp. earns at least as much interest as it pays. Interest obligations are fully covered.

BriaCell Therapeutics Corp. has insufficient data to evaluate this check.

BriaCell Therapeutics Corp.'s short-term assets of $27.40M exceed its short-term liabilities of $5.47M

BriaCell Therapeutics Corp.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

BriaCell Therapeutics Corp.'s return on equity of -147.92%, is lower than 15.00%, indicating bad performance

BriaCell Therapeutics Corp.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

BriaCell Therapeutics Corp. had positive net income in only 0 out of 5 years, indicating unstable earnings

BriaCell Therapeutics Corp. has negative free cash flow, indicating the company is burning cash rather than generating it

BriaCell Therapeutics Corp. has negative free cash flow, indicating cash burn

BriaCell Therapeutics Corp.'s yearly earnings has decreased 661.35% since last year from $-4.79M to $-36.49M, signaling decreasing performance

BriaCell Therapeutics Corp.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -136.31% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

BriaCell Therapeutics Corp. has insufficient revenue history to calculate 3-year revenue CAGR.

BriaCell Therapeutics Corp. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

BriaCell Therapeutics Corp. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

BriaCell Therapeutics Corp. has insufficient data to evaluate this check.

BriaCell Therapeutics Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BriaCell Therapeutics Corp. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

BriaCell Therapeutics Corp. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

BriaCell Therapeutics Corp. has insufficient data to evaluate this check.

BriaCell Therapeutics Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BriaCell Therapeutics Corp. has a price-to-book ratio of 1.05x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

BriaCell Therapeutics Corp. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue